645403-23-2

Basic information

• Product Name: N-adamantan-1-ylmethyl-(2-chloro-5-methoxy)-benzamide
• Synonyms: N-adamantan-1-ylmethyl-(2-chloro-5-methoxy)-benzamide
• CAS NO: 645403-23-2
• Molecular Weight: 333.858
• Mol File: 645403-23-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-adamantan-1-ylmethyl-(2-chloro-5-methoxy)-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-adamantan-1-ylmethyl-(2-chloro-5-methoxy)-benzamide(645403-23-2)
• EPA Substance Registry System: N-adamantan-1-ylmethyl-(2-chloro-5-methoxy)-benzamide(645403-23-2)

Safety Data

• Hazardous Substances Data: 645403-23-2(Hazardous Substances Data)

Upstream product

• 17768-41-1 adamantylmethylamine 
• 100191-61-5 2-chloro-5-methoxybenzoic acid chloride 
• 711-01-3 methyl adamantane-1-carboxylate 
• 6280-89-3 2-chloro-5-methoxybenzoic acid 
• 1501-98-0 1-adamantylmethylamine hydrochloride 
• 5511-18-2 adamantane-1-carboxamide 
• 828-51-3 1-Adamantanecarboxylic acid 

Downstream Products

• 227327-85-7 N-adamantan-1-ylmethyl-(2-chloro-5-hydroxy)-benzamide 

Relevant articles and documents

ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS

The present invention relates to adamantanyl-substituted benzamide compounds and their use as antagonists of the P2X7 purinoreceptor. The invention further relates to methods for the treatment of disease and conditions associated with the P2X7 purinoreceptor.

POLYCYCLIC MOLECULAR COMPOUNDS

This invention relates to compounds of Formula (I), wherein A is a carboaromatic or heteroaromatic ring having one or more substituents; R6 Formula (A) is optionally substituted with one or more substituents; and n is 0, 1 or an integer greater than 1 and when n is 1 or greater the bond or bonds between the carbon atoms may be saturated or unsaturated, which bind the P2X7 receptor with high affinity. This invention also relates to methods for the diagnosis, treatment or monitoring of disorders in which the P2X7 receptor is implicated, in particular the diagnosis, treatment or monitoring of (the progression of) neuroinflammatory and neurodegenerative disorders in a subject.

Hit-to-Lead studies: The discovery of potent adamantane amide P2X 7 receptor antagonists

A Hit-to-Lead optimisation programme was carried out on the adamantane high throughput screening hit 1 resulting in the discovery of a number of potent P2X7 antagonists.